Answers are grounded in this paper and cite their sources.
Case report reveals pilomatrix carcinoma in a Hodgkin lymphoma survivor, indicating potential links to prior treatment.
Pilomatrix carcinoma is a rare, locally aggressive malignant adnexal tumor derived from hair follicle matrix cells. Although secondary malignancies are a well-known concern in Hodgkin lymphoma (HL) survivors, the occurrence of pilomatrix carcinoma in this setting is infrequent. We present the case of a 62-year-old man who was treated for Stage 1 Nodular Sclerosing Classical HL in 2018 with ABVD chemotherapy and radiotherapy. In January 2024, while in remission, he presented with a mass on the right posterior crus, distinct from the previous radiation field. Excision and histopathologic examination revealed pilomatrix carcinoma. Diagnosis was confirmed by immunohistochemistry, which showed a high Ki-67 index, nuclear beta-catenin positivity, and BerEP4 negativity. Owing to the aggressive nature of the tumor, wide re-excision and inguinal lymph node sampling were performed. This case report discusses the diagnostic challenges of this rare tumor and highlights its emergence as a second primary malignancy in a HL survivor, potentially linked to prior chemotherapy and systemic immune dysregulation.
No takes yet. Share an insight, caveat, or question.
Özçelik et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: